RxDoctor Payments Data

Geraldine Simplice, APRN

Primary Care · Norwalk, CTNPI 1841740826

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 21 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Abbott at 37.5% of the total.

$908in general payments, 2019–2025

Across 21 payments — averaging $43.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$341
  • Gilead$168
  • Boehringer Ingelheim$137
  • GSK$82
  • E.r. Squibb & Sons, L.L.C.$66
  • AbbVie$51
  • plus $63 from 3 others

What the payments were for

  • Food & beverage$908100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$908 in reported general payments places this provider in the 75th percentile of 111 primary care providers in Connecticut.

See all primary care providers in Connecticut

Medicare billing

Part B allowed, 2024
$6,412
Medicare patients
52
Services billed
84

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate21$31,880
JardianceEmpagliflozin18$31,587
EliquisApixaban18$23,235
OzempicSemaglutide16$14,518
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$2,785
ShingrixVaricella-Zoster Ge/As01b/Pf16$2,763
Gabapentin55$1,301
Atorvastatin Calcium167$1,201
Gemfibrozil28$908
Metformin Hcl121$742
Lisinopril119$711
Pantoprazole Sodium59$659
Pramipexole DihydrochloridePramipexole Di-Hcl11$628
Amlodipine Besylate135$599
Levothyroxine Sodium37$550

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$137$31,58718 claims
PfizerEliquis$32$23,23518 claims
GSKShingrix$82$2,76316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 111 primary care providers in Connecticut.

Other primary care in Norwalk

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →